News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F) Release: Primary Efficacy and Safety Findings From Phase III Study of Simeprevir in Treatment-Experienced Patients Demonstrate Sustained Virologic Response


5/21/2013 9:19:22 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Stockholm, Sweden — Medivir AB (OMX: MVIR) reports that its partner Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global phase III PROMISE study. Results demonstrated that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir was administered once daily with pegylated interferon and ribavirin.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES